You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
A potent and highly selective D4 dopamine receptor antagonist, with Ki values of > 1700, 770 and 3.5 nM at cloned human D2, D3 and D4 receptors.
Sold with the permission of Merck Sharp and Dohme Ltd.
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 417.38. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|0.1 mM||23.96 mL||119.79 mL||239.59 mL|
|0.5 mM||4.79 mL||23.96 mL||47.92 mL|
|1 mM||2.4 mL||11.98 mL||23.96 mL|
|5 mM||0.48 mL||2.4 mL||4.79 mL|
References are publications that support the biological activity of the product.
Rowley et al (1996) 5-(4-Chlorophenyl)-4-methyl-3-(1-(2-phenylethyl)piperidin-4-yl)isoxazole: a potent, selective antagonist at human cloned DA D4 receptors. J. Med. Chem. 39 1943 PMID: 8642551
Rowley et al (1997) 4-Heterocyclylpiperidines as selective high-affinity ligands at the human DA D4 receptor. J.Med.Chem. 40 2374 PMID: 9240352
If you know of a relevant reference for L-741,742 hydrochloride, please let us know.
View Related Products by Product Action
Keywords: L-741,742 hydrochloride, L-741,742 hydrochloride supplier, selective, D4, antagonists, Dopamine, Receptors, dopaminergic, L741742, 1004, Tocris Bioscience
3 Citations for L-741,742 hydrochloride
Citations are publications that use Tocris products. Selected citations for L-741,742 hydrochloride include:
Bastianetto et al (2006) Prototypical antipsychotic drugs protect hippocampal neuronal cultures against cell death induced by growth medium deprivation. BMC Neurosci 7 28 PMID: 16573831
Root et al (2015) NE activates DA D4 receptors in the rat lateral habenula. J Neurosci 35 3460 PMID: 25716845
Dolma et al (2016) Inhibition of Dopamine Receptor D4 Impedes Autophagic Flux, Proliferation, and Survival of Glioblastoma Stem Cells. Cancer Cell 29 829 PMID: 27300435
Do you know of a great paper that uses L-741,742 hydrochloride from Tocris? Please let us know.
Reviews for L-741,742 hydrochloride
There are currently no reviews for this product. Be the first to review L-741,742 hydrochloride and earn rewards!
Have you used L-741,742 hydrochloride?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Dopamine Receptors Scientific Review
Written by Phillip Strange and revised by Kim Neve in 2013, this review summarizes the history of the dopamine receptors and provides an overview of individual receptor subtype properties, their distribution and identifies ligands which act at each receptor subtype. Compounds available from Tocris are listed.
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.